Targeting cancer metabolism through synthetic lethality-based combinatorial treatment strategies

Purpose of review Targeting cancer metabolism for therapy has received much attention over the last decade with various small molecule inhibitors entering clinical trials. The present review highlights the latest strategies to target glucose and glutamine metabolism for cancer therapy with a particular emphasis on novel combinatorial treatment approaches. Recent findings Inhibitors of glucose, lactate, and glutamine transport and the ensuing metabolism are in preclinical to clinical trial stages of investigation. Recent advances in our understanding of cell-intrinsic and cell-extrinsic factors that dictate dependence on these targets have informed the development of rational, synthetic lethality-based strategies to exploit these metabolic vulnerabilities. Summary Cancer cells exhibit a number of metabolic alterations with functional consequences beyond that of sustaining cellular energetics and biosynthesis. Elucidating context-specific metabolic dependencies and their connections to oncogenic signaling and epigenetic programs in tumor cells represents a promising approach to identify new metabolic drug targets for cancer therapy.
Source: Current Opinion in Oncology - Category: Cancer & Oncology Tags: INNOVATIVE AGENTS AND TREATMENT MODALITIES: Edited by Ahmad Awada and Steven T. Rosen Source Type: research

Related Links:

Broader recommendations on screening for BRCA1/2 genetic mutations published...Read more on AuntMinnie.comRelated Reading: Men need breast cancer screening too MRI finds breast cancer early in women with family history PET tracers help guide breast cancer therapies Breast cancer mutation increases interval cancer risk Screening breast MRI alone OK for high-risk women
Source: Headlines - Category: Radiology Source Type: news
Publication date: Available online 20 August 2019Source: Journal of the Formosan Medical AssociationAuthor(s): Dong-Yi Chen, Wen-Kuan Huang, Victor Chien-Chia Wu, Wen-Cheng Chang, Jen-Shi Chen, Cheng-Keng Chuang, Pao-Hsien ChuImmune checkpoint inhibitors (ICIs) are a novel treatment option for cancer therapy, which help direct the immune system to recognize and target cancer cells. ICIs have been shown to provide significant mortality benefits for cancer patients, but they are also associated with immune-mediated toxicity. Unlike most immune-related adverse events, which are a common occurrence, reversible and can be treat...
Source: Journal of the Formosan Medical Association - Category: General Medicine Source Type: research
Background: Persistent hair disorders resulting from cytotoxic or endocrine agents used in early stages of breast cancer such as alopecia, hirsutism, and madarosis develop in 4-35% of patients, however their impact on quality of life (QoL) has not been reported. The CHANCE study is a prospective, longitudinal study of chemotherapy- and endocrine therapy-induced hair, skin, and nail changes in women with nonmetastatic breast cancer. This preliminary analysis intends to evaluate the impact of permanent hair sequelae of adjuvant breast cancer therapies on patients ’ QoL.
Source: Journal of the American Academy of Dermatology - Category: Dermatology Source Type: research
Publication date: Available online 20 August 2019Source: Seminars in Cancer BiologyAuthor(s): Sobiya Zafar, Sarwar Beg, Sunil K Panda, Mahfoozur Rahman, Khalid S Alharbi, Gaurav K Jain, Farhan J AhmadAbstractCancer, being the most prevalent and resistant disease afflicting any gender, age or social status, is the ultimate challenge for the scientific community. The new generation therapeutics for cancer management has shifted the approach to personalized/precision medicine, making use of patient- and tumor-specific markers for specifying the targeted therapies for each patient. Peptides targeting these cancer-specific sign...
Source: Seminars in Cancer Biology - Category: Cancer & Oncology Source Type: research
In this study, the reduction-responsive polypeptide micelles based on methoxy poly(ethylene glycol)-block-poly(S-tert-butylmercapto-L-cysteine) copolymers (mPEG113-b-PBMLC4, P4M, and mPEG113-b-PBMLC9, P9M) were developed to control the delivery of doxorubicin (DOX) in OS therapy. Compared to free DOX, P4M/DOX and P9M/DOX exhibited 2.6 and 3.5 times increases in the area under the curve (AUC) of pharmacokinetics, 1.6 and 2.0 times increases in tumor accumulation, and 1.6 and 1.7 times decreases the distribution in the heart. Moreover, the selective accumulation of micelles, especially P9M/DOX, in tumors induced stronger ant...
Source: Nanomedicine: Nanotechnology, Biology and Medicine - Category: Nanotechnology Source Type: research
Publication date: December 2019Source: Materials Science in Semiconductor Processing, Volume 104Author(s): Sirish R. Panda, Rohit K. Singh, Barsharani Priyadarshini, Pragyan P. Rath, Pankaj K. Parhi, Trilochan Sahoo, Dindyal Mandal, Tapas Ranjan SahooAbstractThe bioactivity and physical characteristics of CeO2 nanoparticles are significantly dependent on the type of the particle, particle size and defects. Herein, a facile and cost effective microwave-assisted combustion route was used to prepare pure CeO2 nanoparticles (NPs). The samples were thoroughly characterized by various techniques and tested as anti-cancer therape...
Source: Materials Science in Semiconductor Processing - Category: Materials Science Source Type: research
Yuan Loss of cell cycle control is characteristic of tumorigenesis. The protein p21 is the founding member of cyclin-dependent kinase inhibitors and an important versatile cell cycle protein. p21 is transcriptionally controlled by p53 and p53-independent pathways. Its expression is increased in response to various intra- and extracellular stimuli to arrest the cell cycle ensuring genomic stability. Apart from its roles in cell cycle regulation including mitosis, p21 is involved in differentiation, cell migration, cytoskeletal dynamics, apoptosis, transcription, DNA repair, reprogramming of induced pluripotent stem ce...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Review Source Type: research
New J. Chem., 2019, Advance Article DOI: 10.1039/C9NJ03088C, PaperHaiyao Yang, Yanxian Guo, Zhengfei Zhuang, Huiqing Zhong, Chaofan Hu, Zhiming Liu, Zhouyi Guo MoO3 −x is synthesizedvia a one-pot hydrothermal method, with excellent stability against aging, heat, laser exposure and chemical etching. To cite this article before page numbers are assigned, use the DOI form of citation above. The content of this RSS Feed (c) The Royal Society of Chemistry
Source: RSC - New J. Chem. latest articles - Category: Chemistry Authors: Source Type: research
Abstract PURPOSE: To evaluate the use of individualized piano instruction (IPI) for improving cognition among breast cancer survivors. PARTICIPANTS & SETTING: Six participants were included in an eight-week piano program with three data collection time points at baseline, midpoint, and postintervention. Participants were recruited from the breast cancer clinic of a university cancer center in South Florida. METHODOLOGIC APPROACH: Neurocognitive, psychosocial, and self-report assessments were conducted to determine potential benefits and program feasibility, including the NIH Toolbox® Cognition Ba...
Source: Oncology Nursing Forum - Category: Nursing Authors: Tags: Oncol Nurs Forum Source Type: research
First description in the literature of incidental saddle pulmonary embolus diagnosed on18F ‐labelled fluoro‐2‐deoxyglucose positron emission tomography/computed tomography by seeing pulmonary infarction and right‐sided myocardial uptake. This will alert clinicians about the importance of these signs and direct emergent of further investigation and therapy. 18F ‐labelled fluoro‐2‐deoxyglucose positron emission tomography/computed tomography (18F ‐FDG PET/CT) is used extensively in the setting of cancer staging and in assessing cancer treatment response. Oncology patients have a sevenfold risk of developing p...
Source: Respirology Case Reports - Category: Respiratory Medicine Authors: Tags: Case Report Source Type: research
More News: Cancer | Cancer & Oncology | Cancer Therapy | Clinical Trials